https://www.biospace.com/cabaletta-bio-expands-executive-leadership-team-with-appointments-of-samik-basu-m-d-to-chief-scientific-officer-and-heather-harte-hall-msc-to-chief-compliance-officer
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients...
executive leadership teamcabalettabioexpandsappointments
https://www.globenewswire.com/news-release/2018/11/08/1648061/0/en/Cabaletta-Bio-Emerges-Out-of-University-of-Pennsylvania-to-Develop-CAAR-T-Cell-Technology-to-Treat-B-Cell-mediated-Autoimmune-Diseases.html
-- Signs exclusive license agreement and multi-year sponsored research agreements with University of Pennsylvania -- Completes $38 million Series A...
cabalettabiouniversitypennsylvania
https://www.pharmaceutical-technology.com/data-insights/caba-201-cabaletta-bio-idiopathic-inflammatory-myopathy-iim-likelihood-of-approval/
CABA-201 is under clinical development by Cabaletta Bio and currently in Phase II for Idiopathic Inflammatory Myopathy (IIM).
inflammatory myopathycababioidiopathiciim